immunomodulatory treatment by rituximab
Phase 3Monoclonal antibody
immunomodulatory treatment by rituximab is one of 25 small molecule programs targeting Psychiatric Disorder. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Psychiatric Disorder
#DrugCompanyPhaseTrials
1Chantix
PfizerApproved
Wellbutrin
GSKApproved
Lexapro
AbbVieApproved
Nicorette
PfizerApproved
Chantix
PPrism Pharmaceuticals
Approved
Nicotine Free Cigarettes
PfizerApproved
Pitocin
RRetrophin
Approved
Suboxone
IIndivior Inc.
Approved
Brintellix
TakedaPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital, Bordeaux